Malaria remains a major public health challenge across Nigeria, making antimalarial medications some of the most frequently dispensed drugs in local clinics, maternity homes, and hospitals. Midwives must understand how these drugs work to treat infections effectively and counsel mothers properly. Treatment depends heavily on whether the malaria parasite has invaded the red blood cells, causing symptoms, or remains dormant in certain body tissues. Early and accurate diagnosis using rapid diagnostic tests or microscopy should always precede drug administration to prevent misuse and slow down drug resistance.
Artemisinin-Based Combination Therapies are the gold standard for treating uncomplicated malaria in Nigeria. These regimens combine an artemisinin derivative—which works rapidly to clear the bulk of the parasites from the bloodstream—with a longer-acting partner drug that mops up any remaining organisms.
Combining these two different mechanisms of action makes it much harder for the malaria parasite to develop resistance compared to when single drugs are used alone.
Treating malaria differs drastically depending on whether the infection is uncomplicated or has progressed to a severe, life-threatening stage. For uncomplicated malaria, oral ACTs are taken over a three-day course. Patients must complete the full dose even if they start feeling better by day two.
Severe malaria is a medical emergency characterized by complications like severe anemia, cerebral malaria, or organ failure. It requires immediate hospital admission and parenteral therapy—specifically, intravenous or intramuscular artesunate as the first-line treatment, followed by a full three-day course of oral ACT once the patient can swallow safely.
Preventative antimalarial strategies protect populations who face the highest risk of severe illness and death. In Nigerian communities, pregnant women and infants are primary targets for preventive measures.
Intermittent Preventive Treatment in pregnancy involves giving a full treatment dose of sulfadoxine-pyrimethamine at routine antenatal care visits starting after the first trimester. For infants, seasonal malaria chemoprevention is deployed during peak transmission periods in certain geographical zones. Alongside drugs, midwives must consistently promote insecticide-treated bed nets and environmental sanitation.
Managing malaria in pregnancy requires careful selection of drugs to safeguard both the mother and the developing fetus. During the first trimester, artemisinin-based therapies are generally avoided unless no other safe alternative exists, and quinine combined with clindamycin is often preferred. After the first trimester, standard ACTs are safe and effective.
For nursing mothers, most standard antimalarial drugs pass into breast milk in small amounts, but they are generally considered safe for the infant at therapeutic doses. Midwives should reassure breastfeeding mothers that treating their own infection protects the infant from secondary exposure.
Like all medications, antimalarials can produce mild side effects such as nausea, dizziness, or headache, which midwives should explain to patients beforehand so they do not stop taking their drugs. More critically, drug resistance threatens malaria control efforts across West Africa. When patients share doses, take incomplete courses, or buy fake medications, surviving parasites mutate. Midwives play a frontline role in educating communities on completing full drug doses and discouraging self-medication with unverified herbal concoctions or leftover tablets.